SummaryRMgm-5639
|
||||||||
*RMgm-5639| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 40392232 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
| Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Zeeshan M, Tewari R |
| Name Group/Department | University of Nottingham |
| Name Institute | School of Life Sciences |
| City | Nottingham |
| Country | UK |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5639 |
| Principal name | ALAN-GFP |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | ALLAN-GFP exhibited a diffuse nucleoplasmic signal in trophozoites and schizonts with distinct focal points adjacent to dividing DNA, consistent with a role in mitotic regulation. By late schizogony, the ALLAN signal had diminished |
| Gametocyte/Gamete | In male and female gametocytes and during zygote to ookinete transformation, ALLAN-GFP showed a spherical distribution around Hoechst-stained nuclear DNA and was enriched to form distinct focal points. |
| Fertilization and ookinete | In male and female gametocytes and during zygote to ookinete transformation, ALLAN-GFP showed a spherical distribution around Hoechst-stained nuclear DNA and was enriched to form distinct focal points. |
| Oocyst | During oocyst development ALLAN-GFP exhibited distinct focal points adjacent to dividing DNA |
| Sporozoite | Not tested |
| Liver stage | During liver schizogony ALLAN-GFP exhibited distinct focal points adjacent to dividing DNA |
| Additional remarks phenotype | Mutant/mutation Analysis of a mutant lacking expression of SUN1 (RMgm-5636) showed the following: Analysis of a mutant expressing a C-terminal GFP-tagged version of SUN1 (RMgm-5637) showed the following: The SUN1 Interactome Reveals Associations with Nuclear Envelope, ER and Chromatin components. PbSUN1 interacted with proteins harbouring a divergent carbohydrate binding domain, such as the allantoicase-like protein ALCC1, referred to as ALLAN (PBANKA_1144200)(see RMgm-5638 and RMgm-5639). Other mutants |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1144200 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1368300 | ||||||||||||||||||||||||||
| Gene product | non-structural maintenance of chromosomes element 1, putative | ||||||||||||||||||||||||||
| Gene product: Alternative name | ALAN | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | GFP | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | To generate GFP-tagged lines for SUN1, and ALLAN, a region of each gene downstream of the ATG start codon was amplified, ligated to the p277 vector, and transfected as previously described. The p277 vector includes a human DHFR cassette, providing resistance to pyrimethamine. Gene-deletion targeting vectors for SUN1, and ALLAN were created using the pBS1105 DHFR plasmid. This plasmid contains polylinker sites flanking a Toxoplasma gondii dhfr/ts expression cassette, which provides resistance to pyrimethamine, as previously described previously (Saini et al., 2017). To construct these vectors, PCR primers N1511 and N1512 were used to amplify a 1,1094 bp fragment of the 5' upstream sequence to sun1 from genomic DNA, which was then inserted into the ApaI and HindIII restriction sites upstream of the dhfr/ts cassette in the pBS-DHFR plasmid. A 776 bp fragment from the 3' flanking region of sun1 gene generated with primers N1513 and N1514, was inserted downstream of the dhfr/ts cassette using EcoRI and XbaI restriction sites. The same method was applied for allan amplifying the upstream (1044 bp) and downstream (1034 bp) sequences and inserted to pBS-DHFR plasmid. The linear targeting sequence was released using ApaI/XbaI. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||